[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chlamydia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chlamydia":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,64,92,124,149,174,205,234,266,363,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100628220","healthy-expectancy-through-routine-antenatal-sti-screening-100628220",false,"NCT07458802","Healthy Expectancy Through Routine Antenatal STI Screening","Screening and Treatment for Chlamydia Trachomatis Infection to Prevent Preterm Birth","HERA","Inclusion Criteria:\n\n1. Asymptomatic for cervicovaginitis at first ANC (i.e., not syndromically treated for an STI by clinic midwives at first ANC)\n2. Age ≥ 15 years\n3. Currently pregnant\n4. ≤20 weeks gestation (based on gestational age in obstetric record or last menstrual period if gestational age missing from record)\n5. Attending first ANC visit\n6. Residence in Gaborone, Bostwana or surrounding villages through the time of delivery\n7. Mentally competent to understand study procedures or give informed consent",true,"FEMALE","15 Years",{"count":21,"type":22},2000,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will evaluate whether routine screening and treatment for two common sexually transmitted infections, chlamydia and gonorrhoea, during pregnancy can reduce preterm birth and other poor birth outcomes in Botswana, and whether this approach is affordable and cost-effective for the health system.\n\nAbout 2,000 pregnant women attending their first antenatal care visit at up to 10 government clinics in Botswana will be invited to join the study. All women will first receive the usual antenatal care services provided in Botswana, including routine health checks and HIV and syphilis testing. Women who enroll in the study will be randomly assigned to one of two groups:\n\n1. Standard of care group: Women receive routine antenatal care only.\n2. Intervention group: In addition to routine antenatal care, women are screened for chlamydia and gonorrhoea using self-collected vaginal swabs at their first antenatal care visit and again in the third trimester.\n\nThe main outcome of the study is whether screening and treating chlamydia and gonorrhoeae reduces preterm birth (before 37 weeks). Other outcomes include low birth weight, very preterm birth, and maternal health conditions.",[28,29,30,31,32,33,34,35],"Antenatal Health","Antenatal Care","STI","Chlamydia Trachomatis Infection in Pregnancy","Chlamydia","Chlamydia Trachomatis","Chlamydia Trachomatis Infection","Preterm Birth",[37,38,39,40,41,42,43,30,44,45,46,47,48,49,50],"antenatal health","antenatal screening","chlamydia","chlamydia trachomatis","chlamydia screening","chlamydia treatment","pregnancy screening","STI screening","STI in pregnancy","preterm delivery","Botswana","CT infection","chlamydia in pregnancy","birth outcomes","RECRUITING","2026-06-30",{"date":54,"type":55},"2026-07-02","ACTUAL",{"date":57,"type":55},"2026-05-25",{"date":59,"type":22},"2030-07-01",{"name":61,"class":62},"Adriane Wynn","OTHER",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":17,"sex":72,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":63},"100628637","improving-clinic-delivery-of-hiv-related-anal-health-services-100628637","NCT07464236","Improving Clinic Delivery of HIV-related Anal Health Services","Partnering to Enhance Anal Health Communication and HIV-related Evidence-based Services","PEACHES 2","Inclusion Criteria:\n\nStaff participants (\"Strategy Recipients\" and \"Strategy Recipients\")\n\n* employed at one of eight Coastal Family Health Center clinics at the time of the survey\n* over age 18 years old\n\nPatient participants (\"Patients\")\n\n* accessing sexual health services at one of eight Coastal Family Health Center clinics in the last 12 months\n* over 18 years old\n\nExclusion Criteria:\n\n* Staff or patients who are unable to provide informed consent (e.g., significant cognitive impairment)\n* Individuals currently incarcerated or in state custody\n* Patients whose only visits are for non-HIV, non-STI issues and who do not meet the EMR-based eligibility criteria above","ALL","18 Years",{"count":75,"type":22},8,[25],"This project will test ways to reduce stigma in healthcare settings so that more providers offer, and more patients receive, important anal sex-related HIV services, including anorectal sexually transmitted infection (STI) testing, preventive medications, and cancer screening. By evaluating these stigma-reduction strategies in eight clinics in the Mississippi Delta, a region with high rates of HIV and STIs, the research team will learn whether and how these approaches work to improve access to care. The results will help guide healthcare systems in using the most effective methods to reduce stigma, making it easier for people to get prevention services and improving public health.",[79,80,32,81],"HIV","Gonorrhea","Anal Cancer Squamous Cell","NOT_YET_RECRUITING","2026-06-02",{"date":85,"type":55},"2026-06-03",{"date":87,"type":22},"2026-08-01",{"date":89,"type":22},"2030-07-31",{"name":91,"class":62},"Albert Einstein College of Medicine",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":18,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100572833","phase-4-doxycycline-prophylaxis-for-prevention-of-sexually-transmitted-infections-100572833","NCT06738407","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young Adult Females in the United States","Inclusion Criteria:\n\n* Age 13-29 years, inclusive;\n* Self-reports GC, CT, and\u002For early syphilis diagnosis in the 12 months prior to screening;\n* Self-reports condomless (oral, vaginal, and\u002For anal) intercourse at least once in the 30 days prior to screening\n* Is at least 45 kilograms (99.2 pounds) in weight\n* Fluent in English (able to read, speak, and understand English);\n* Willing to undergo all required study procedures; and\n* Willing to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Is male;\n* Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months;\n* Documented history of tetracycline allergy or self-reports an allergy to tetracyclines;\n* Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline ;\n* Current or planned use of doxycycline for a prolonged period (\\> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis;\n* Prolonged antibiotic use (\\> 2 weeks) within the last 30 days prior to enrollment;\n* Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing;\n* Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or\n* Any other medical condition, medical\u002Fbehavioral intervention, or other conditions that, in the opinion of the clinical site Project Lead (PL)\u002FInvestigator of Record (IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results.","13 Years","29 Years",{"count":102,"type":22},760,[104],"PHASE4","The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.",[80,32,107,108],"Syphilis","Sexually Transmitted Infections (STIs)",[110,111,112,113],"Sexually Transmitted Infections","STIs","Doxycycline Prophylaxis","Doxycycline","2026-05-12",{"date":116,"type":55},"2026-05-15",{"date":118,"type":55},"2026-02-27",{"date":120,"type":22},"2028-06-15",{"name":122,"class":62},"Westat",13,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":17,"sex":72,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":63},"100491394","effectiveness-of-relationship-education-for-reducing-hiv-incidence-among-men-who-have-sex-with-men-100491394","NCT05678556","Effectiveness of Relationship Education for Reducing HIV Incidence Among Men Who Have Sex With Men","Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex With Men","all2GETHER","Inclusion Criteria:\n\n* Cisgender men, transgender women and men, non-binary individuals\n* Had condomless anal sex with 2 or more serodiscordant\u002Funknown-status cisgender male partners in the last 6 months\n* Aged 16-34 years\n* Lab-test confirmed HIV-negative\n* Read and speak English at 8th grade level or better\n* Internet access\n* Agree to audio recording of intervention sessions\n* Provides address to receive HIV\u002FSTI test supplies\n* For dyads, both partners may enroll if they meet the above criteria- partners who are aged 35+ and\u002For HIV-positive may enroll in a more limited capacity\n\nExclusion Criteria:\n\n-Participants assigned female at birth who identify as women are not eligible","16 Years","34 Years",{"count":135,"type":22},5000,[25],"The purpose of this study is to upgrade an existing relationship education and HIV prevention program. This program is designed for gay, bisexual, queer, and transgender and non-binary people who partner with cisgender men. This means the program is designed for gay, bisexual and queer men, including both cisgender and transgender men. It is also designed for transgender and non-binary people who partner with cisgender men, including both transfeminine and transmasculine people. The investigators aim to test the effectiveness of this updated program among couples and single people.\n\nParticipants will complete online surveys and get tested for Chlamydia and Gonorrhea. Participants will be tested for urethral and rectal Chlamydia and Gonorrhea. Participants will also complete at-home point-of-care HIV testing, with confirmatory testing for preliminary positive results. They will also participate in our program on relationship education and HIV prevention. Study staff will follow up with participants for up to 2 years.\n\nAll participants will be randomized into one of two different conditions: the all2GETHER program or no program. \"Randomized\" means that it is completely up to chance which condition participants will be put into. Participants have a 50% chance of being assigned to either condition, similar to a coin toss. Participants should expect that they will be in this research study for 2 years. Participation in this study will be done remotely - participants will never need to come into a research lab.",[139,32,80],"Hiv","2026-05-06",{"date":142,"type":55},"2026-05-08",{"date":144,"type":55},"2022-12-15",{"date":146,"type":22},"2028-08-31",{"name":148,"class":62},"Northwestern University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":17,"sex":72,"minAge":19,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":63},"100549025","a-seek-test-and-treat-intervention-to-reduce-chlamydia-trachomatis-disparities-100549025","NCT06428643","A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities","A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities in Black Youth Living in the Deep South","Inclusion Criteria:\n\n* Identifies as African American or Black\n* 15-26 years of age\n* Lives or spends most of their time in Orleans Parish\n* Had vaginal sex at least once\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Unable to speak or understand English\n* Previously enrolled in the study\n* Known to be pregnant\n* Known HIV positive status","26 Years",{"count":158,"type":22},2322,[25],"This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.",[32,80,139,107],[163,164],"Screening","Expedited Treatment","2026-04-30",{"date":167,"type":55},"2026-05-05",{"date":169,"type":55},"2025-08-14",{"date":171,"type":22},"2029-09-01",{"name":173,"class":62},"Tulane University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":17,"sex":72,"minAge":73,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":191,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":63},"100574980","integrated-care-versus-usual-care-for-opioid-use-disorder-and-infectious-diseases-in-veterans-100574980","NCT06766331","Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","Integrating Infectious Diseases Screening and Treatment With Medication Assisted Therapy for Veterans With Opioid Use Disorder","Inclusion Criteria:\n\n* US Veteran\n* Able to provide written informed consent in English\n* Living in the community (Nassau, Suffolk, Kings, Queens, Bronx, Westchester, Rockland counties, NY)\n* Documented diagnosis of moderate to severe opioid use disorder\n* Seeking care at the Northport VA substance use disorder clinic for opioid use disorder treatment\n* Willing to have HIV, HBV, HCV, or bacterial STI testing to determine negative or positive status\n* Persons who test negative for HIV need to meet CDC PrEP eligibility criteria in the 6 months prior to enrollment\n\nExclusion Criteria:\n\n* Severe medical or psychiatric disability making participation unsafe\n* Unable to provide written consent\n* PrEP exclusion: HIV positive test; HBV positive test",{"count":182,"type":22},60,[25],"Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans. Treatment of OUD with medication assisted therapy is highly effective, however this often occurs independently of infectious diseases care. This project will test out a new model that combines infectious diseases and OUD care within one VA clinic appointment. This new care model may improve the health of Veterans and reduce cost and time required for Veterans who often need to attend multiple outpatient appointments.",[186,79,187,80,32,107,188,189,190],"Opioid Use Disorder","Hepatitis C Virus","Sexually Transmitted Infection","Integrated Care","Medications for Opioid Use Disorder",[192,79,193,194],"Hepatitis C","sexually transmitted diseases","Opioid-Related Disorders","2026-04-21",{"date":197,"type":55},"2026-04-24",{"date":199,"type":22},"2028-04-03",{"date":201,"type":22},"2029-06-29",{"name":203,"class":204},"VA Office of Research and Development","FED",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":17,"sex":72,"minAge":132,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100632686","evaluation-of-free-sti-testing-pilot-projects-in-lucerne-and-zurich-switzerland-100632686","NCT07516912","Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland","feSTI: Evaluation of Free HIV and STI Testing and Counselling Services for Young and Disadvantaged Populations in Lucerne and Zurich","feSTI","Inclusion Criteria:\n\n* taking part in the pilot programmes\n* understand the study information\n* 16 years of age or older\n\nExclusion Criteria:\n\n* not eligible for the pilot programmes\n* not understanding the study information\n* less than 16 years old",{"count":214,"type":22},1800,"OBSERVATIONAL","The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.",[218,32,80,107,219],"HIV (Human Immunodeficiency Virus)","HCV",[221,222,79,223,224],"Voluntary counselling and testing","sexually transmitted infections","implementation of free testing","barriers to care","2026-04-02",{"date":227,"type":55},"2026-04-08",{"date":229,"type":22},"2026-04-07",{"date":231,"type":22},"2029-02-28",{"name":233,"class":62},"University of Zurich",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":17,"sex":242,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":63},"100623497","phase-4-the-efficacy-of-doxycycline-post-exposure-prophylaxis-for-preventing-stis-among-msm-in-bangkok-thailand-100623497","NCT07397403","The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.","The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing Sexually Transmitted Diseases (Gonorrhea, Chlamydia, Syphilis) Among Men Who Have Sex With Men in Bangkok, Thailand.","ThaiDoxyPEP","Inclusion Criteria:\n\nBiological male, aged not over 60 years\n\nThai nationality\n\nAble to read, communicate, and understand the Thai language\n\nMen who have sex with men (MSM), aged 18 years or older and not over 60 years\n\nHaving at least one of the following risk factors:\n\nA history of condomless sex, or condom failure (breakage, leakage, or slippage), via any sexual route with at least two sexual partners within the past 3 months\n\nA diagnosis of gonorrhea, chlamydia, or syphilis within the past 6 months\n\nCurrent use of HIV pre-exposure prophylaxis (PrEP)\n\nWilling and able to participate in study procedures (e.g., able to return to the clinic for scheduled testing for gonorrhea, chlamydia, and syphilis; able to complete doxycycline use records; and able to receive follow-up phone calls from the research team)\n\nWilling and able to provide written informed consent to participate in the study\n\n\\-\n\nExclusion Criteria:\n\n* History of allergy to tetracycline-class antibiotics\n\nDiagnosed with syphilis and not yet treated, or currently receiving treatment with benzathine penicillin G or doxycycline\n\nReceipt of benzathine penicillin G within the past 12 weeks\n\nPrior receipt of a gonorrhea vaccine\n\nCurrent use of medications or products that may interact with doxycycline, including:\n\nVitamin A derivatives (e.g., isotretinoin, acitretin)\n\nAntiepileptic drugs (e.g., phenytoin, carbamazepine, phenobarbital)\n\nImmunosuppressive agents (e.g., methotrexate)\n\nMedications for heart failure or cardiac arrhythmias (e.g., digoxin)\n\nAnticoagulants (e.g., warfarin)\n\nUse of oral or injectable medications that affect blood cells, such as anticancer drugs, chemotherapy, systemic corticosteroids, or targeted therapies\n\nHistory of renal impairment (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m²) or hepatic impairment (AST or ALT \\> 3 times the upper limit of normal)\n\nUncontrolled or unstable underlying diseases, such as hematologic disorders, cancer, autoimmune diseases, or neurological disorders\n\nSevere medical or psychiatric conditions that, in the investigator's judgment, may increase study-related risk or impair the participant's ability to provide informed consent\n\nAlcohol dependence (inability to control alcohol consumption, withdrawal symptoms upon reduction or cessation, or continued use despite harm) or illicit drug dependence (regular, uncontrolled use) within the past 12 months prior to enrollment, which may affect doxycycline use for STI prevention\n\nPrevious participation in this study with prior randomization","MALE","18 Days","60 Days",{"count":246,"type":22},400,[104],"The objective of this research is to evaluate the efficacy and safety of doxycycline in MSM for preventing sexually transmitted infections (gonorrhea, chlamydia, and syphilis) in Thailand\n\nParticipation in this study will last approximately 12 weeks and will include 2-3 clinic visits, along with 10-11 follow-up phone contacts over a period of 11 weeks.",[250,80,32],"Syphilis Infection",[252,253,107,254,32,255],"DoxyPEP","MSM","gonorrhea","Prevention","2026-02-02",{"date":258,"type":55},"2026-02-09",{"date":260,"type":55},"2025-10-06",{"date":262,"type":22},"2027-05-31",{"name":264,"class":265},"Bangrak STIs Center","OTHER_GOV",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":17,"sex":72,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":277,"conditions":278,"keywords":336,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":63},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":276,"type":22},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,32,323,324,325,326,327,328,329,330,331,332,333,334,335],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":356,"type":55},"2026-01-22",{"date":358,"type":55},"2025-12-18",{"date":360,"type":22},"2027-09-30",{"name":362,"class":62},"Institut Pasteur du Cambodge",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":17,"sex":18,"minAge":371,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":391,"locationsCount":63},"100589209","assessing-acceptability-and-feasibiity-of-sti-self-swab-testing-to-be-offered-at-the-time-of-telemed-medication-abortion-provision-100589209","NCT06951438","Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision","STI Self-swab Testing At the Time of Telemed Medication Abortion Provision","STAMP","Inclusion Criteria:\n\n1. Patients of the Queen Medical Center Options Center clinic seeking telemedicine medication abortion.\n2. Patients for whom, according to the CDC guidelines for STI Testing11, STI testing is indicated, or patients who desire STI screening\n3. Age 14 and over\n4. Can speak and read English\n5. Displays capacity for informed consent\n\nExclusion Criteria:\n\n1. Home address that is not located in the state of Hawai'i\n2. Incarcerated\n3. Unwilling to perform vaginal swab collection","14 Years",{"count":373,"type":22},75,[25],"The goal of this interventional study is to provide more access to STI testing for patients who seek abortion care through telemedicine, particularly for those whose access to STI testing is otherwise limited. The main questions it aims to answer are:\n\nWhat is the acceptability, feasibility, and utilization of self-collected STI screening at the time of telemedicine medication abortion provision?\n\nHow does the uptake of such a service among patients receiving telemedicine abortion care compare to the population of patients who seek in-person medication abortion care?\n\nWhat are the positivity rates for STIs in among patients receiving telemedicine medication abortion care compared to the positivity rates for a contemporaneous, in-clinic population?\n\nWhat is the average time to between testing and treatment for patients who test positive for an STI using the self-collection service?\n\nResearchers will compare the intervention group to a contemporaneous, in-clinic population on uptake of STI screening, as well as on positivity rates for the STIs tested.\n\nParticipants will be asked to perform self-swab collection for STI testing for gonorrhea, chlamydia, and trichomonas. They will be instructed to send their specimens to a lab using prepaid postage. Upon completion of sample collection and shipping, they will be asked to complete a survey assessing basic demographic information, as well as acceptability and feasibility of the intervention. Patients who test positive for an STI will be promptly provided\u002Freferred to treatment.",[377,80,32,378],"Sexually Transmitted Disease (STD)","Trichomonas Infection",[380,381,382,383,384],"STI testing","telemedicine","medication abortion","self-swab collection","vaginal swab","2025-06-25",{"date":387,"type":55},"2025-06-26",{"date":389,"type":55},"2025-05-22",{"date":52,"type":22},{"name":392,"class":62},"Queen's Medical Center",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":72,"minAge":73,"maxAge":401,"enrollmentInfo":402,"targetDuration":404,"studyType":215,"phases":4,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":63},"100464312","vienna-hiv-infection-via-sex-study-100464312","NCT05326061","Vienna HIV Infection Via Sex Study","Characterization of Patients at High Risk for the Acquisition of Sexually Transmitted Infection With the Human Immunodeficiency Virus (HIV) - a Clinical Study","HIVEX","Inclusion Criteria:\n\n1. High risk for acquiring HIV defined as followed: HIV-negative MSM and transgender individuals who (i) do not use condoms consistently with casual partners and\u002For with HIV-positive partners who are not on treatment and\u002For (ii) recently acquired an STI and\u002For (iii) recently used PEP and\u002For (iv) frequently engage in 'chemsex'.\n2. Age \\>18 years and \\\u003C100 years.\n3. Written informed consent for this registry study.\n\nExclusion Criteria:\n\n1\\. Withdrawal of the written informed consent.","100 Years",{"count":403,"type":22},500,"5 Years","The main objective of this prospective observational cohort study is to investigate the epidemiology, the risk factors and ultimately the incidence of novel HIV infections among individuals at high risk for acquiring HIV via sex practices.",[407,408,409,80,32,107],"HIV Infections","HIV Pre-Exposure Prophylaxis","Sexually Transmitted Diseases","2022-04-06",{"date":412,"type":55},"2022-04-13",{"date":414,"type":55},"2020-07-01",{"date":416,"type":22},"2030-12",{"name":418,"class":62},"Medical University of Vienna"]